T1 bladder cancer in Norway: treatment and survival

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cancer Registry of Norway. Cancer in Norway 2018 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2019.
   Google Scholar
• Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Comperat EM, et al. European association of urology guidelines on non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76(5):639–657.
   PubMed Web of Science ®Google Scholar
• Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Cin Oncol. 2015;33(6):643–650.
   PubMed Web of Science ®Google Scholar
• Klaassen Z, Kamat AM, Kassouf W, et al. Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol. 2018;74(5):597–608.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466. discussion 475–7.
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2018;73(6):925–933.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, et al.;European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54(2):303–314.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970.
   PubMed Web of Science ®Google Scholar
• Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–1231.
   PubMed Web of Science ®Google Scholar
• Montironi R, Lopez-Beltran A, Scarpelli M, et al. 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. European Urology Supplements. 2009;8(5):453–457.
   Web of Science ®Google Scholar
• Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat Med. 2004;23(1):51–64.
   PubMed Web of Science ®Google Scholar
• Nelson CP, Lambert PC, Squire IB, et al. Flexible parametric models for relative survival, with application in coronary heart disease. Statist Med. 2007;26(30):5486–5498.
   PubMed Web of Science ®Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. The Stata J. 2009;9(2):265–290.
   Web of Science ®Google Scholar
• Azzouz H, Cauberg EC, De Reijke TM. Controversies in the management of T1 urothelial bladder cancer. Minerva Urol Nefrol. 2011;63(4):309–315.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Kunath F, Coles B, et al. Intravesical bacillus calmette-guérin versus mitomycin C for Ta and T1 bladder cancer . Cochrane Database Syst Rev. 2020;1:CD011935.
   PubMedGoogle Scholar
• Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol. 2014;65(2):267–269.
   PubMed Web of Science ®Google Scholar
• Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience. 2019;13:905
   PubMed Web of Science ®Google Scholar
• Sjostrom C, Thorstenson A, Strock V, et al. Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. Scand J Urol. 2018;52(3):186–193.
   PubMed Web of Science ®Google Scholar
• Canter D, Egleston B, Wong YN, et al. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis. Urol Oncol. 2013;31(6):866–870.
   PubMed Web of Science ®Google Scholar
• Thorstenson A, Hagberg O, Ljungberg B, et al. Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. Scand J Urol. 2016;50(4):292–297.
   PubMed Web of Science ®Google Scholar
• Swedish National Registry of Urinary Bladder Cancer. Available from: https://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase–och-urinrorscancer/rapporter/urinblasa_arsrapport_2018_final.pdf.
   Google Scholar
• Denzinger S, Fritsche HM, Otto W, et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur. Urol. 2008;53(1):146–152.
   PubMed Web of Science ®Google Scholar
• Schrier BP, Hollander MP, van Rhijn BW, et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004;45(3):292–296.
   PubMed Web of Science ®Google Scholar
• Moschini M, Sharma V, Dell'oglio P, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117(4):604–610.
   PubMed Web of Science ®Google Scholar
• Jahnson S, Hosseini Aliabad A, Holmang S, et al. Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. Scand J Urol. 2016;50(1):14–20.
   PubMed Web of Science ®Google Scholar
• Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int. 2016;118(1):44–52.
   PubMed Web of Science ®Google Scholar
• Palou J, Pisano F, Sylvester R, et al. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World J Urol. 2018;36(10):1621–1627.
   PubMed Web of Science ®Google Scholar
• Dobruch J, Daneshmand S, Fisch M, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol. 2016;69(2):300–310.
   PubMed Web of Science ®Google Scholar